Opis działalności
Alkermes plc, is a biopharmaceutical company that researches, develops and commercializes pharmaceutical products to address the unmet medical needs of patients in the fields of neuroscience and oncology in the USA, Ireland and worldwide. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, as well as a pipeline of product candidates in development for neurological disorders and cancer. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland
Zarząd & Rada nadzorcza
| CEO |
| Richard Pops |
| Zarząd |
| Iain Brown, Sandy Coombs, Grace Doyle, Colleen Ellwanger, Heather Faulds, David Gaffin, Anne Giovanoni, Markus Haeberlein, Thomas Harvey, Julie Lekstrom Himes, Craig Hopkinson, Blair Jackson, Michael Landine, Todd Nichols, Peter Norman, Declan O’Connor, Bhaskar Rege, Kanchan Relwani, Stephen Schiavo, James Schoener |
| Rada nadzorcza |
| Richard F. Pops, Emily Peterson Alva, Shane M. Cooke, David A. Daglio, Richard B. Gaynor, Dr. Cato T. Laurencin, Brian P. McKeon, Nancy L. Snyderman, Andy Wilson, Christopher I. Wright, Nancy J. Wysenski |
Dane firmy
| Nazwa: |
Alkermes plc |
| Adres: |
Connaught House, 1 Burlington Road Dublin 4,Dublin D04 C5Y6 |
| Telefon: |
+353 1 772 8000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.alkermes.com/ |
| Przemysł: |
Służba zdrowia |
| Sektor: |
Przemysł Farmaceutyczny |
| Podsektor: |
Przemysł Farmaceutyczny |
| Koniec roku finansowego: |
31.12 |
| Free float: |
- |
| Data IPO: |
- |
